4Wedam SB,Low JA.Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J].Clin Oncol,2006,24(5):769.
5Dincer M,Altundag K.Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension[J].Ann Phamacother,2006,40(12):2278-2279.
6Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
7Miles DA.Management of toxicity in patients receiving therapy withBevacizumab[J].Eur J Cancer,2008,6(6):29-39.
8Scappaticc FA,Skillings JR,Holden SN,et al.Arterial thrombo-embolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab[J].Natl Cancer Inst,2007,99(16):1232-1239.
9Eremina V,Baelde HJ,Quggin SE.Role 0f the VEGF-a signaling pathway in glomerulus:evidence for crosstalk between components of the glomerular filtration barrier[J].Nephron Physiol,2007,106(2):32-37.
10Hurwitz H,Saini S.Bevacizumab in the treatment of metastatic colo-rectal:safety profile and managerment of advense events[J].Semin Oncol,2006,33(5):S26-S34.
